CoChat

Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease

Open access

The DOI matches its Crossref record; 152 of the 152 references it cites were found in a registry or an index.

Abstract

Effective medical management for sickle cell disease (SCD) remains elusive. As a prevalent and severe monogenic disorder, SCD has been long considered a logical candidate for gene therapy. Significant progress has been made in moving toward this goal. These efforts have provided substantial insight into the natural regulation of the globin genes and illuminated challenges for genetic manipulation of the hematopoietic system. The initial γ-retroviral vectors, next-generation lentiviral vectors, and novel genome engineering and gene regulation approaches each share the goal of preventing erythrocyte sickling. After years of preclinical studies, several clinical trials for SCD gene therapies are now open. This review focuses on progress made toward achieving gene therapy, the current state of the field, consideration of factors that may determine clinical success, and prospects for future development.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2015-09-618587

Cites

152 of 152 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 152 references

Research works printed but not linked: 1

  1. Cavazzana, 2015, Outcomes of gene therapy for B-thalassemia major and severe sickle cell disease via transplantation of autologous hematopoietic stem cells transduced ex vivo with a lentiviral beta globin vector., Haematologica, 100, 171

Cited by

See all 203

Metadata

Authors
Hoban, M. D., Orkin, S. H., & Bauer, D. E.
Affiliations
Boston Children's Hospital (US)
Venue
Blood
Published
2016-02-18
Volume
127
Issue
7
Pages
839-848
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2255869136
Cited by
194
References
152
Citations by year
2026: 11 · 2025: 12 · 2024: 19 · 2023: 13 · 2022: 8 · 2021: 18 · 2020: 25 · 2019: 23 · 2018: 21 · 2017: 23 · 2016: 20
FWCI
3.39
Type
journal article
Language
en
Open access
Locations
  • Blood (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Heart, Lung, and Blood Institute (P01HL032262, R01HL032259, T32HL007574)
  • National Institute of Diabetes and Digestive and Kidney Diseases (P30DK049216, K08DK093705)
Topics
  • Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
Keywords
sickle cell disease, gene therapy, globin gene regulation, hematopoietic stem cells, gammaretroviral vectors, lentiviral vectors, genome editing, gene expression regulation, erythrocyte sickling, clinical trials
MeSH terms
Anemia, Sickle Cell, Clinical Trials as Topic, Gene Expression Regulation, Genetic Vectors, Humans, Genetic Therapy, Genome, Human

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease. https://app.cochat.ai/papers/10.1182/blood-2015-09-618587
The paper
Hoban, M. D., Orkin, S. H., & Bauer, D. E. (2016). Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease. Blood. https://doi.org/10.1182/blood-2015-09-618587

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.